Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Elizabeth K Lee; Zhenying Tan-Wasielewski; Carol Aghajanian; Robert L Coleman; Jennifer Curtis; Michelle S Hirsch; Ursula A Matulonis; Lewis C Cantley; Gordon B Mills; L Austin Doyle; Joyce F Liu

doi:10.1016/j.gore.2020.100546

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecol Oncol Rep. 2020 Feb 3:32:100546. doi: 10.1016/j.gore.2020.100546. eCollection 2020 May.

Authors

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
² Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States.
³ Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
⁴ Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁵ Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
⁶ Department of Pathology, Women's and Perinatal Division, Brigham and Women's Hospital, Boston, MA, United States.
⁷ Meyer Cancer Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, United States.
⁸ Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁹ Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, United States.

Abstract

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.

Keywords: AKT inhibitor; MK-2206; PI3K/AKT pathway; PTEN; Platinum resistant ovarian cancer; Serous ovarian carcinoma.

Publication types

Case Reports

Abstract

Publication types

Grants and funding